Stephane Roche
CEO, AdaptBio Therapeutics
ADAPT: An Emerging Platform of Antibody CDR-H3-based Scaffolds for the Discovery of Novel Classes of Protein-Protein Interaction Inhibitors
Company Description
Aberrant and misregulated protein–protein interactions (PPIs) are implicated in a plethora of human diseases; Yet the development of small-molecule PPI inhibitors continues to lag behind the remarkable success of monoclonal antibody drugs, which dominates this therapeutic space. To enter this space, our team at AdaptBio Inc. has pioneered the ADAPT platform technology (short for Adaptive Design of Antibody Paratopes into Therapeutics) inspired by antibody CDR-H3s to engineer next-generation therapeutic peptides targeting PPIs. In this talk, we will discuss how this scaffolding technology can faithfully miniaturized CDR-H3 antibody-mimics, providing powerful tools to devise chemical probes and preclinical drug candidates to greatly accelerate the discovery of PPI inhibitors, .
Bio
Stéphane is the founder and CEO of AdaptBio Therapeutics (Est. in 2024). He has over 15 years of experience in synthetic and medicinal chemistry in diverse therapeutic areas working on small-molecule natural products and peptide drugs. This rich experience in drug discovery drives his interest in solving complex issues at the interface of science, medicine, and business strategy to create novel medicines that will improve the lives of patients and their families.